Licart (Diclofenac Epolamine) Patent Expiration, LOE Window & CMS Spending

Licart (Diclofenac Epolamine) by Ibsa Institut Biochimique Sa: FDA Orange Book LOE 2035-02-20, 0 AB generics, $10.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIbsa Institut Biochimique Sa
FDA Application & PathwayN206976 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-02-20
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.1M
2024 Medicare Part D Spend$7.9M
2024 Medicaid Spend$2.2M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 24.2% 2-yr change)